Lyell Immunopharma Inc
LYEL
Get informed when a big investor buys or sells
+ FollowMarket Cap$310.81M
Close$
$0.50
96.1% downside
Current Fair Value
96.1% downsideOvervalued by 96.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $310.81 Million |
|---|---|
| Enterprise Value | $259.53 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-16.06 |
| Beta | -0.06 |
| Outstanding Shares | 21,876,000 |
Return
| Return on Equity | -90.04% |
|---|---|
| Return on Assets | -70.28% |
| Return on Invested Capital | 28.88% |
Valuation & Multiples
| P/E Ratio | -0.78 |
|---|---|
| PEG | 1.46 |
| Price to Sales | - |
| Price to Book Ratio | 1.07 |
| Enterprise Value to Revenue | 8371.84 |
| Enterprise Value to EBIT | 2.87 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | 0.14 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-2.37
Average shareholder expectationRevenue Estimate
$5,500
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-2.02
Average shareholder expectationRevenue Estimate
$4,600
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3425▲ 34.25% |
|---|---|
| Total Calls | 12,000▲ Infinity% |
| Total Puts | 4,110▼ 85.43% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 54.74%▼ 7.70% |
|---|---|
| Total Invested | $237.23M▼ 32.28% |
| Investors Holding | 76▲ 6.00% |
ESG Score
No data
About Lyell Immunopharma Inc
189 employees